search
Back to results

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

Primary Purpose

Recurrent Bacterial Vaginosis

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Oral tinidazole
Sponsored by
Kaiser Permanente
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent Bacterial Vaginosis focused on measuring Bacterial vaginosis, Tinidazole, Vaginitis

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Current infection with bacterial vaginosis 2 previous episodes of bacterial vaginosis within the past 12 months Willing to use contraception Able to swallow pills Willing to refrain from douching or using vaginal products Willing to refrain from alcohol consumption 24 hours before and for 72 hours after taking study medication (tinidazole) Exclusion Criteria: Women with same sex partners Menstruating at initial exam Presence of yeast, a sexually transmitted disease, or other vaginal infection Purulent cervical discharge Use of any drug for bacterial vaginosis or yeast within the past 2 weeks prior to enrollment Pregnant or nursing Taking lithium Taking blood thinners (anticoagulation therapy) Use of any investigational drug within the previous 30 days Active HPV infection requiring treatment Use of drugs that suppress the immune system History of alcoholism Taking disulfiram

Sites / Locations

  • Kaiser Permanente

Outcomes

Primary Outcome Measures

Efficacy of oral tinidazole for treatment of recurrent bacterial vaginosis
Efficacy of oral tinidazole for prevention of recurrent bacterial vaginosis

Secondary Outcome Measures

Patient satisfaction with tinidazole for recurrent bacterial vaginosis

Full Information

First Posted
May 9, 2006
Last Updated
July 31, 2012
Sponsor
Kaiser Permanente
search

1. Study Identification

Unique Protocol Identification Number
NCT00324142
Brief Title
A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis
Official Title
A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Withdrawn
Why Stopped
Study Terminated Prematurely
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kaiser Permanente

4. Oversight

5. Study Description

Brief Summary
This is a study of the drug tinidazole for women with recurrent bacterial vaginosis. Half of the participants will get the drug for 10 days, the other half will get the drug for 10 days and then twice a week for 12 weeks.
Detailed Description
This study will recruit 60 women with recurrent bacterial vaginosis. These women must have a current infection to be enrolled in the study and have had two other infections within the past 12 months. After initial screening to make sure that the vaginal symptoms are due to bacterial vaginosis and not the results of a different infection, all of the women will receive tinidazole (a drug that is similar to metronidazole) by mouth for 10 days. At the end of the 10 days, patients will be re-examined. Those women who are free of bacterial vaginosis will enter the second phase of the study, where half of the patients will continue to take tinidazole twice a week for twelve weeks and the other half will take no medication. During this time participants will be examined by the study doctor every 4 weeks to see how effective the treatment has been at preventing the recurrence of bacterial vaginosis. At the end of the 12 weeks, women who are still free of bacterial vaginosis will be seen for 3 more visits over 3 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Bacterial Vaginosis
Keywords
Bacterial vaginosis, Tinidazole, Vaginitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Oral tinidazole
Primary Outcome Measure Information:
Title
Efficacy of oral tinidazole for treatment of recurrent bacterial vaginosis
Title
Efficacy of oral tinidazole for prevention of recurrent bacterial vaginosis
Secondary Outcome Measure Information:
Title
Patient satisfaction with tinidazole for recurrent bacterial vaginosis

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Current infection with bacterial vaginosis 2 previous episodes of bacterial vaginosis within the past 12 months Willing to use contraception Able to swallow pills Willing to refrain from douching or using vaginal products Willing to refrain from alcohol consumption 24 hours before and for 72 hours after taking study medication (tinidazole) Exclusion Criteria: Women with same sex partners Menstruating at initial exam Presence of yeast, a sexually transmitted disease, or other vaginal infection Purulent cervical discharge Use of any drug for bacterial vaginosis or yeast within the past 2 weeks prior to enrollment Pregnant or nursing Taking lithium Taking blood thinners (anticoagulation therapy) Use of any investigational drug within the previous 30 days Active HPV infection requiring treatment Use of drugs that suppress the immune system History of alcoholism Taking disulfiram
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer Gunter, MD
Organizational Affiliation
Kaiser Permamente
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

We'll reach out to this number within 24 hrs